Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-002259-24
    Sponsor's Protocol Code Number:KF5503-73
    National Competent Authority:Poland - Office for Medicinal Products
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-12-19
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPoland - Office for Medicinal Products
    A.2EudraCT number2014-002259-24
    A.3Full title of the trial
    Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of intravenous tapentadol solution for injection for the treatment of post-surgical pain in children aged from birth to less than 2 years, including preterm neonates.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Use of intravenous tapentadol solution for injection for pain after surgery in children from newborn to less than 2 years old, including preterm neonates.
    A.4.1Sponsor's protocol code numberKF5503-73
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1157-3228
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/279/2013
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGrünenthal GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGrünenthal GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGrünenthal GmbH
    B.5.2Functional name of contact pointGrünenthal Clinical Trial Helpdesk
    B.5.3 Address:
    B.5.3.1Street AddressZieglerstr. 6
    B.5.3.2Town/ cityAachen
    B.5.3.3Post code52078
    B.5.3.4CountryGermany
    B.5.4Telephone number+49241569 3223
    B.5.6E-mailClinical-Trials@grunenthal.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTapentadol 1 mg/mL solution for injection
    D.3.2Product code CG5503
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTapentadol hydrochloride
    D.3.9.1CAS number 175591-09-0
    D.3.9.2Current sponsor codeCG5503
    D.3.9.3Other descriptive nameTAPENTADOL HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB32145
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe post-operative pain
    E.1.1.1Medical condition in easily understood language
    Acute post-operative pain
    E.1.1.2Therapeutic area Diseases [C] - Symptoms and general pathology [C23]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10036286
    E.1.2Term Post-operative pain
    E.1.2System Organ Class 100000004863
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the trial is to collect serum concentration data of tapentadol and its major metabolite tapentadol-O-glucuronide after the administration of a single dose of intravenous tapentadol solution for injection in children aged from birth to less than 2 years, including preterm neonates, after a qualifying procedure (either a surgical procedure or alternatively a medical procedure in preterm neonates) that routinely produces moderate to severe acute pain requiring opioid treatment. The concentration data will be used to characterize the pharmacokinetic parameters of tapentadol using population and physiologically-based pharmacokinetic approaches.
    This will enable data based recommendations for the use of tapentadol in children of different ages.
    E.2.2Secondary objectives of the trial
    To evaluate the safety and tolerability of a single dose of tapentadol intravenous solution in the population studied.
    To explore the effect of intravenous tapentadol solution for injection on moderate to severe pain that, in the opinion of the investigator, requires treatment with an opioid, using validated age appropriate scales.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. The subject's parent(s) or legal guardian(s) have given written informed consent to participate.
    2. Male or female subject aged from birth to less than 2 years, including preterm neonates.
    3. For subjects in age subgroup 3: Gestational age at least 37 weeks. For subjects in age subgroup 4: A gestational age of 24 weeks to less
    than 37 weeks with a postmenstrual age of less than or equal to 41 weeks.
    4. (Criterion deleted)
    5. Subject is not obese (e.g., a body weight above the 97th percentile range for children based on the World Health Organization weight
    charts, with a minimum body weight of 1.5 kg.
    6. Physical status rated not higher than P3 on the American Society of Anesthesiologists physical status classification in subjects in age
    subgroup 1 and age subgroup 2.
    7. Subject has undergone a qualifying procedure (surgery or alternatively for subjects in age subgroup 4, a medical procedure ) that, in the investigator's opinion, would reliably produce moderate to severe pain requiring opioid
    treatment.
    8. Subjects in age subgroup 3 or age subgroup 4 must be in an intensive care unit or comparable unit with high medical surveillance.
    9. At the time of allocation to Investigational Medicinal Product, subject has a sedation score that is not higher than 2 (moderately sedated) on
    the University of Michigan Sedation Scale with the exception of subjects who are mechanically ventilated in age subgroup 3 and age subgroup 4.
    10. Subject has a reliable venous vascular access for pharmacokinetic blood sampling.
    E.4Principal exclusion criteria
    1. The subject's parent(s) or legal guardian(s) is an employee of the investigator or trial site with direct involvement in trials under their
    direction, or is a family member of the employees or the investigator.
    2. Subject has been previously exposed to tapentadol.
    3. Subject has received an experimental drug/device within 28 days before allocation to IMP, or less than 10 times the drug's half-life,
    whichever is longer.
    4. Concomitant participation in another clinical trial with an experimental drug or experimental device for the duration of this trial.
    5. Subject has undergone brain surgery.
    6. (Criterion deleted)
    7. Subject has a history or current condition of seizure disorder or traumatic or hypoxic brain injury or other conditions that may increase
    the intracranial pressure.
    8. Subject has a history or current condition of moderate to severe renal or hepatic impairment or respiratory conditions that would put the subject at risk for developing respiratory depression.
    9. Subject has signs or symptoms of congestive heart failure or hemorrhagic disorder following surgery.
    10. Subject has a concomitant disease or disorder that in the opinion of the investigator can affect or compromise subject's safety during the
    trial participation.
    11. Subject has cognitive or developmental impairment that would affect trial participation.
    12. Subject has a clinically relevant history of hypersensitivity, allergy, or contraindication to tapentadol (or ingredients).
    13. Subject has clinically relevant abnormal ECG in the investigator's judgment or QTcF >460 ms (unless value is a consequence of cardiac
    surgery and is not considered clinically significant).
    14. Subject has clinically significant abnormal laboratory values or exclusionary hepatic or renal parameters, or pathological jaundice.
    15. Sepsis that requires treatment with catecholamines.
    16. Subject has been administered a prohibited medication.
    17. The mother of a newborn subject or the breastfeeding mother of a subject was administered a prohibited medication.
    18. Subject has post-operative clinically unstable vital signs, or clinically unstable respiratory condition (unless subject is mechanically ventilated
    in age subgroup 3 and 4).
    19. Peripheral oxygen saturation <92% (acyanotic subjects) or <75% (cyanotic subjects) with or without oxygen administration or for age
    sub-group 4 a clinically significant decrease in oxygen saturation at the time of allocation to IMP.
    20. Subject requires continuous positive airway pressure or mechanical ventilation, at the time of allocation to IMP, for subjects in age subgroup
    1 and 2.
    E.5 End points
    E.5.1Primary end point(s)
    • Pharmacokinetic evaluation based on serum concentrations of tapentadol, and
    • Pharmacokinetic evaluation based on serum concentrations of tapentadol-O-glucuronide.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Blood samples taken within 10 hours of IMP intake at 3 time points per subject.
    E.5.2Secondary end point(s)
    No secondary endpoints
    E.5.2.1Timepoint(s) of evaluation of this end point
    No secondary endpoints
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Staggered recruitment by age starting with the recruitment of subjects in age group 1.
    At least 4 subjects must be enrolled and dosed in an older age subgroup to assess targeted exposure and safety before enrollment of subjects in the next younger age subgroup.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 32
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Yes
    F.1.1.2.1Number of subjects for this age range: 8
    F.1.1.3Newborns (0-27 days) Yes
    F.1.1.3.1Number of subjects for this age range: 8
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 16
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Minors incapable of giving consent.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state37
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 38
    F.4.2.2In the whole clinical trial 38
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-02-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-11-27
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-09-27
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 04:48:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA